Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J
Department of Medicine, Huddinge Hospital, Sweden.
Br J Haematol. 1995 Mar;89(3):637-9. doi: 10.1111/j.1365-2141.1995.tb08377.x.
Cladribine is an effective therapy for hairy cell leukaemia (HCL), but the standard regime is frequently complicated by neutropenic fever and prolonged T-cell depression. We studied 102 patients with active HCL following treatment with various doses of cladribine given for 7 d. Two patients received 1 mg cladribine/m2/d without toxicity or effect. Eight subsequent patients received 2 mg cladribine/m2/d, and normalized cytopenia as quickly as 94 control patients receiving a standard dose (3.4 mg/m2 or 0.085 mg/kg), with significantly less lymphopenia and a similar complete remission rate.
克拉屈滨是治疗毛细胞白血病（HCL）的有效疗法，但标准治疗方案常伴有中性粒细胞减少性发热和T细胞长期抑制等并发症。我们研究了102例活动性HCL患者，给予不同剂量的克拉屈滨治疗7天。2例患者接受1mg克拉屈滨/m²/天，未出现毒性反应或疗效不佳。随后8例患者接受2mg克拉屈滨/m²/天治疗，血细胞减少恢复正常的速度与94例接受标准剂量（3.4mg/m²或0.085mg/kg）治疗的对照患者一样快，淋巴细胞减少明显较少，完全缓解率相似。
